Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 471

1.

The prognostic value of nuclear morphometric analysis in serous ovarian carcinoma.

Palmer JE, Sant Cassia LJ, Irwin CJ, Morris AG, Rollason TP.

Int J Gynecol Cancer. 2008 Jul-Aug;18(4):692-701. Epub 2007 Oct 18.

PMID:
17944918
2.

The prognostic and predictive value of syntactic structure analysis in serous carcinoma of the ovary.

Palmer JE, Sant Cassia LJ, Irwin CJ, Morris AG, Janssen EA, Baak JP, Rollason TP.

Int J Gynecol Pathol. 2008 Apr;27(2):191-8. doi: 10.1097/PGP.0b013e31815699f6.

PMID:
18317224
3.

Prognostic value of measurements of angiogenesis in serous carcinoma of the ovary.

Palmer JE, Sant Cassia LJ, Irwin CJ, Morris AG, Rollason TP.

Int J Gynecol Pathol. 2007 Oct;26(4):395-403.

PMID:
17885489
4.
5.

Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.

Skírnisdóttir I, Seidal T.

Int J Gynecol Cancer. 2011 Aug;21(6):1024-31. doi: 10.1097/IGC.0b013e31821dc906.

PMID:
21792012
6.

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.

Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL, Ramirez PT, Gershenson DM.

Gynecol Oncol. 2008 Mar;108(3):510-4. Epub 2007 Dec 26.

PMID:
18155273
7.

Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up.

Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR.

Am J Surg Pathol. 2005 Jun;29(6):707-23.

PMID:
15897738
8.

The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.

Protopapas A, Diakomanolis E, Bamias A, Milingos S, Markaki S, Papadimitriou C, Dimopoulos AM, Michalas S.

Eur J Gynaecol Oncol. 2004;25(2):225-9.

PMID:
15032288
9.

Clinical value of morphometric and DNA flow cytometric variables as independent predictors of survival in epithelial ovarian carcinoma: a 5-year follow-up study.

Veerman MM, van der Wurff AA, van de Water M, Kruitwagen RF, Feijen HW, Vos MC.

Int J Gynecol Pathol. 2009 Sep;28(5):432-41. doi: 10.1097/PGP.0b013e31819b2864.

PMID:
19696612
10.

Prognostic significance of tumor cell morphometry, histopathology, and clinical parameters in advanced ovarian carcinoma.

Ludescher C, Weger AR, Lindholm J, Oefner D, Hausmaninger H, Reitsamer R, Mikuz G.

Int J Gynecol Pathol. 1990;9(4):343-51.

PMID:
2246093
11.

Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential.

Crispens MA, Bodurka D, Deavers M, Lu K, Silva EG, Gershenson DM.

Obstet Gynecol. 2002 Jan;99(1):3-10.

PMID:
11777502
12.

Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas.

van der Zee AG, Hollema H, Suurmeijer AJ, Krans M, Sluiter WJ, Willemse PH, Aalders JG, de Vries EG.

J Clin Oncol. 1995 Jan;13(1):70-8.

PMID:
7799045
13.

Grading ovarian serous carcinoma using a two-tier system.

Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG.

Am J Surg Pathol. 2004 Apr;28(4):496-504.

PMID:
15087669
14.

Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Winter WE 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP; Gynecologic Oncology Group.

J Clin Oncol. 2008 Jan 1;26(1):83-9. Epub 2007 Nov 19.

15.

Nuclear size distinguishes low- from high-grade ovarian serous carcinoma and predicts outcome.

Hsu CY, Kurman RJ, Vang R, Wang TL, Baak J, Shih IeM.

Hum Pathol. 2005 Oct;36(10):1049-54. Epub 2005 Sep 8.

PMID:
16226103
16.

VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection.

Engels K, du Bois A, Harter P, Fisseler-Eckhoff A, Kommoss F, Stauber R, Kaufmann M, Nekljudova V, Loibl S.

J Clin Pathol. 2009 May;62(5):448-54. doi: 10.1136/jcp.2008.063859. Epub 2009 Jan 6.

PMID:
19126566
17.

[Construction and utilization of the prognostic model of serous ovarian adenocarcinoma].

Yang R, Feng J, Fang XZ, Bai F, Cheng YX, Liu C, Zhu W, Li L.

Zhonghua Fu Chan Ke Za Zhi. 2006 Jul;41(7):459-63. Chinese.

PMID:
17083811
18.

Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.

Storey DJ, Rush R, Stewart M, Rye T, Al-Nafussi A, Williams AR, Smyth JF, Gabra H.

Cancer. 2008 May 15;112(10):2211-20. doi: 10.1002/cncr.23438.

19.

The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.

Gorovetz M, Baekelandt M, Berner A, Trope' CG, Davidson B, Reich R.

Gynecol Oncol. 2006 Dec;103(3):831-40. Epub 2006 Aug 17.

PMID:
16919315
20.

The prognostic value of morphometry in advanced epithelial ovarian cancers.

Katsoulis M, Lekka J, Vlachonikolis I, Delides GS.

Br J Cancer. 1995 Oct;72(4):958-63.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk